Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2020

June 2020 | 136 pages | ID: IC8560916B0EN
Global Markets Direct

Abstracts

Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2020, provides an overview of the Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline landscape.
Avian influenza A (H7N9) is a subtype of influenza viruses. This infection is seen both in humans and birds. Infection is caused when a person is exposure to infected poultry or contaminated environments. Symptoms include fever, cough that produces sputum, headache, myalgia and general malaise. Treatment includes antiviral drugs

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H7N9 Subtype Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H7N9 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 13 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 4 and 3 molecules, respectively.
Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H7N9 Subtype Infections (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H7N9 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Influenza A Virus, H7N9 Subtype Infections - Overview
Influenza A Virus, H7N9 Subtype Infections - Therapeutics Development
Influenza A Virus, H7N9 Subtype Infections - Therapeutics Assessment
Influenza A Virus, H7N9 Subtype Infections - Companies Involved in Therapeutics Development
Influenza A Virus, H7N9 Subtype Infections - Drug Profiles
Influenza A Virus, H7N9 Subtype Infections - Dormant Projects
Influenza A Virus, H7N9 Subtype Infections - Discontinued Products
Influenza A Virus, H7N9 Subtype Infections - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by AIM ImmunoTech Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by AusBio Ltd, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Beijing Tiantan Biological Products Co Ltd, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Codagenix Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by CSL Ltd, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by EpiVax Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Genentech Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Greffex Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Hualan Biological Bacterin Co Ltd, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Johnson & Johnson, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medicago Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Medigen Vaccine Biologics Corp, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Moderna Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by NanoViricides Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Ology Bioservices Inc, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Pneumagen Ltd, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Sanofi, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Seqirus Ltd, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Shanghai Institute of Biological Products Co Ltd, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Shionogi & Co Ltd, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Pipeline by Virion Biotherapeutics, H1 2020
Influenza A Virus, H7N9 Subtype Infections - Dormant Projects, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Influenza A Virus, H7N9 Subtype Infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

AIM ImmunoTech Inc
AusBio Ltd
Beijing Tiantan Biological Products Co Ltd
Cocrystal Pharma Inc
Codagenix Inc
CSL Ltd
EpiVax Inc
Genentech Inc
Greffex Inc
Hualan Biological Bacterin Co Ltd
Inovio Pharmaceuticals Inc
Johnson & Johnson
Medicago Inc
Medigen Vaccine Biologics Corp
Moderna Inc
NanoViricides Inc
New Amsterdam Sciences Inc
Ology Bioservices Inc
Pneumagen Ltd
Sanofi
Seqirus Ltd
Shanghai Institute of Biological Products Co Ltd
Shionogi & Co Ltd
Virion Biotherapeutics